63 research outputs found
Ki67 Proliferation Index as a Tool for Chemotherapy Decisions During and After Neoadjuvant Aromatase Inhibitor Treatment of Breast Cancer: Results From the American College of Surgeons Oncology Group Z1031 Trial (Alliance)
To determine the pathologic complete response (pCR) rate in estrogen receptor (ER) –positive primary breast cancer triaged to chemotherapy when the protein encoded by the MKI67 gene (Ki67) level was > 10% after 2 to 4 weeks of neoadjuvant aromatase inhibitor (AI) therapy. A second objective was to examine risk of relapse using the Ki67-based Preoperative Endocrine Prognostic Index (PEPI)
International consensus on the clinical management of Inflammatory Breast Cancer from the Morgan Welch Inflammatory Breast Cancer research program 10th anniversary conference
Implications of constructed biologic subtype and its relationship to locoregional recurrence following mastectomy
Surgery of the Intact Primary Tumor for Patients Presenting With Metastatic Breast Cancer: Palliation or Cure?
Recommended from our members
Primary Locoregional Treatment in Metastatic Breast Cancer: A Reply.
Recommended from our members
Primary Locoregional Treatment in Metastatic Breast Cancer: A Reply.
Underuse of Trimodality Treatment Affects Survival for Patients With Inflammatory Breast Cancer: An Analysis of Treatment and Survival Trends From the National Cancer Database
Effect of hormone receptor status and local treatment on overall survival for early-stage breast cancer.
- …